Investor Relations

Print   Email  
Stock price graph
     

Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis.

View all »   RSSRecent Releases

Jun 16, 2015
Ocera Therapeutics to Present at the JMP Securities Life Sciences Conference

May 29, 2015
Ocera Therapeutics to Present at the Jefferies 2015 Healthcare Conference

Investors